Business Description
Alphamab Oncology
ISIN : KYG0330A1013
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.46 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -2.46 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.53 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 33.1 | |||||
3-Year EPS without NRI Growth Rate | 24.2 | |||||
3-Year FCF Growth Rate | 21.3 | |||||
3-Year Book Growth Rate | -13 | |||||
Future 3-5Y EPS without NRI Growth Rate | 21.49 | |||||
Future 3-5Y Total Revenue Growth Rate | 46.4 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.33 | |||||
9-Day RSI | 44.75 | |||||
14-Day RSI | 51.27 | |||||
6-1 Month Momentum % | -38.93 | |||||
12-1 Month Momentum % | -74.53 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.61 | |||||
Quick Ratio | 4.42 | |||||
Cash Ratio | 4.22 | |||||
Days Inventory | 477.94 | |||||
Days Sales Outstanding | 20.98 | |||||
Days Payable | 150.23 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | 1.05 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 79.3 | |||||
Operating Margin % | -103.47 | |||||
Net Margin % | -84.9 | |||||
FCF Margin % | -75.96 | |||||
ROE % | -12.59 | |||||
ROA % | -9.81 | |||||
ROIC % | -32.13 | |||||
ROC (Joel Greenblatt) % | -36.04 | |||||
ROCE % | -10.74 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.89 | |||||
PB Ratio | 2.2 | |||||
Price-to-Tangible-Book | 2.04 | |||||
EV-to-EBIT | -10.61 | |||||
EV-to-EBITDA | -16.57 | |||||
EV-to-Revenue | 8.56 | |||||
EV-to-FCF | -12.39 | |||||
Price-to-Net-Current-Asset-Value | 3.06 | |||||
Price-to-Net-Cash | 3.57 | |||||
Earnings Yield (Greenblatt) % | -9.42 | |||||
FCF Yield % | -5.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Alphamab Oncology Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 32.796 | ||
EPS (TTM) (€) | -0.029 | ||
Beta | 0.29 | ||
Volatility % | 117.05 | ||
14-Day RSI | 51.27 | ||
14-Day ATR (€) | 0.021036 | ||
20-Day SMA (€) | 0.4613 | ||
12-1 Month Momentum % | -74.53 | ||
52-Week Range (€) | 0.21 - 1.53 | ||
Shares Outstanding (Mil) | 962.97 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Alphamab Oncology Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Alphamab Oncology Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Alphamab Oncology Frequently Asked Questions
What is Alphamab Oncology(STU:3NK)'s stock price today?
When is next earnings date of Alphamab Oncology(STU:3NK)?
Does Alphamab Oncology(STU:3NK) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |